Transcatheter Aortic-Valve Replacement for Inoperable Severe Aortic Stenosis

20121,334 citationsJournal Articlebronze Open Access

Authors

Raj Makkar

Gregory P. Fontana · Vascular Institute of New York

Hasan Jilaihawi

Samir Kapadia · Cleveland Clinic

Augusto D. Pichard · MedStar Washington Hospital Center

Pamela S. Douglas · Duke University

Vinod H. Thourani · Emory University

Vasilis Babaliaros

Abstract

Among appropriately selected patients with severe aortic stenosis who were not suitable candidates for surgery, TAVR reduced the rates of death and hospitalization, with a decrease in symptoms and an improvement in valve hemodynamics that were sustained at 2 years of follow-up. The presence of extensive coexisting conditions may attenuate the survival benefit of TAVR. (Funded by Edwards Lifesciences; ClinicalTrials.gov number, NCT00530894.).

Topics & Keywords

Cardiac Valve Diseases and Treatments Infective Endocarditis Diagnosis and Management Cardiac Imaging and Diagnostics

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 366, Issue 18, pp. 1696-1704

DOI: 10.1056/nejmoa1202277

Field-Weighted Citation Impact: 100.57